Prognostic value of soluble ST2 in adults with congenital heart disease by Geenen, L.W. et al.
  999Geenen LW, et al. Heart 2019;105:999–1006. doi:10.1136/heartjnl-2018-314168
Original research article
Prognostic value of soluble ST2 in adults with 
congenital heart disease
laurie W geenen,1 Vivan J M Baggen,1 annemien e van den Bosch,1 
Jannet a eindhoven,1 Judith a a e cuypers,1 Maarten Witsenburg,1 eric Boersma,1,2 
Jolien W roos-hesselink   1 
Congenital heart disease
To cite: geenen lW, 
Baggen VJM, van den 
Bosch ae, et al. Heart 
2019;105:999–1006.
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2018- 314168).
1Department of cardiology, 
erasmus Mc, University Medical 
centre rotterdam, rotterdam, 
the netherlands
2Department of clinical 
epidemiology, erasmus Mc, 
University Medical centre 




hesselink, Department of 
cardiology, erasmus Mc, 
University Medical centre 
rotterdam, rotterdam 3000 
ca, the netherlands;  j. roos@ 
erasmusmc. nl
received 19 september 2018
revised 23 December 2018
accepted 3 January 2019
Published Online First 
30 January 2019
 ► http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2019- 314699
© author(s) (or their 
employer(s)) 2019. no 
commercial re-use. see rights 
and permissions. Published 
by BMJ.
AbsTrACT
Objective soluble suppression of tumourigenicity-2 
(sst2) is upregulated as response to myocardial stress 
and may be a potential biomarker for risk stratification in 
patients with adult congenital heart disease (achD). this 
study aimed to investigate the release of sst2 and its 
association with cardiovascular events in achD.
Methods in this prospective cohort study, 602 
consecutive patients with achD visiting the outpatient 
clinic were included (2011–2013). the association 
between sst2 and a primary composite endpoint of all-
cause mortality, heart failure, hospitalisation, arrhythmia, 
thromboembolic events or cardiac interventions was 
investigated using multivariable cox regression.
results sst2 was measured in 590 (98%) patients 
(median age 33 [25–41] years, 42% women). after 
a median follow-up of 5.8 [iQr 5.1–6.2) years, 225 
(38.5%) reached the primary endpoint. sst2 was 
significantly associated with the primary endpoint 
when adjusted for age, sex, creatinine and n  terminal 
pro-B type brain natriuretic peptide (nt-proBnP) (hr 
per twofold higher sst2: 1.28, 95% ci 1.03 to 1.58, 
p=0.025). this association negated when adjusted for 
clinical variables and nt-proBnP (hr per twofold higher 
sst2: 1.19, 95% ci 0.96 to 1.48, p=0.106). stratified 
analysis in complex achD did show a significant 
association between sst2 and the primary endpoint 
when adjusted for clinical variables and nt-proBnP (hr 
per twofold higher sst2: 1.31, 95% ci 1.01 to 1.69, 
p=0.043). sex-specific analysis showed an association 
between sst2 and the primary endpoint in women (hr 
per twofold higher sst2 1.80, 95% ci 1.30 to 2.49, 
p<0.001) but not in men (hr per twofold higher sst2 
1.19, 95% ci 0.90 to 1.56, p=0.223).
Conclusions sst2 is a promising novel biomarker in 
patients with achD, specifically in complex achD and 
women. Future research is warranted to elucidate sex-
specific and diagnosis-specific differences.
InTrOduCTIOn
With the improvement of genomic technology, 
new pathways and biomarkers related to cardiac 
remodelling are discovered. One of these recently 
discovered biomarkers is soluble suppression of 
tumourigenicity-2 (sST2), a member of the inter-
leukin-1 receptor family. The expression of sST2 
is upregulated by cardiac myocytes as a response 
to stress or injury.1 Higher sST2 levels are found 
in patients with severe heart failure (HF) and are 
associated with an increased mortality.2 sST2 is 
therefore seen as a promising new biomarker in 
the ongoing search for the ideal HF biomarker for 
optimal risk stratification. Adequate risk stratifica-
tion can contribute to better individualised thera-
peutic strategies, improving survival and reducing 
morbidity. Additionally, it can contribute to more 
detailed tailoring of information about the prog-
nosis of an individual patient.
While sST2 has been extensively investigated 
in several disease populations such as patients 
with myocardial infarction3 4 and chronic and 
acute HF,2 5 6 only very limited data are available 
in adult congenital heart disease (ACHD).7 The 
ACHD population is rapidly expanding because 
of improved therapies during childhood and are 
characterised by a high burden of HF, arrhyth-
mias and (re-)interventions at adult age.8 Proper 
risk stratification is therefore of major importance. 
It is unknown whether sST2 is associated with 
more complex ACHD and whether it yields addi-
tive prognostic value. Therefore, this study aimed 
to investigate the release of sST2 among different 
types of ACHD and its association with cardiovas-
cular events in patients with moderate and complex 
ACHD, beyond the conventional biomarker 
N terminal pro-B type brain natriuretic peptide 
(NT-proBNP).
MeThOds
study population and healthy controls
In this prospective observational cohort study, 
consecutive adults patients with moderate or 
complex9 congenital heart disease who routinely 
visited the outpatient clinic of our centre between 
April 2011 and April 2013 were included. Exclu-
sion criteria were: age <18 years, pregnancy, 
mild cardiac lesion (isolated atrial or ventricular 
septal defect), severe renal dysfunction (creati-
nine >200 µmol/L) or not capable of understanding 
or signing informed consent. At the day of study 
inclusion, all patients underwent physical examina-
tion by a cardiologist, 12-lead electrocardiography, 
transthoracic echocardiography and venous blood 
sampling. Follow-up was ensured by protocolled 
structural annual visits to the ACHD outpatient 
clinic during the first four subsequent years. The 
study protocol conforms to the principles outlined 
in the Declaration of Helsinki. All participating 
patients gave written informed consent. The study 
protocol and echocardiographic imaging analysis 
have been described in more detail previously.10 11
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A healthy control cohort consisting of self-declared healthy 
volunteers was recruited between January 2014 and December 
2014. All volunteers underwent physical examination, electro-
cardiography, echocardiography and venous blood sampling on 
the same day. More details have been described previously.12
biomarker assessment
Venous blood samples were taken at the day of study inclusion 
for study purpose only. No clinical decisions were based on 
any biomarker. Blood samples were transferred to the clinical 
chemistry laboratory within 2 hours. NT-proBNP and creatinine 
were directly determined in fresh blood samples. The rest of the 
samples were aliquoted and stored at −80°C until batch anal-
ysis was performed. Serum sST2 was measured on the Presage 
ST2 assay (Critical Diagnostics, San Diego, California, USA), a 
monoclonal electrochemiluminescense immunoassay (limit of 
quantitation 2.4 ng/mL). Samples were exposed to two thaw-
freeze cycles before analysed. The Presage ST2 assay is not 
significantly affected by sample freeze–thaw cycles and is stable 
up to 15 freeze–thaw cycles. sST2 was measured once in study 
patients and twice in healthy volunteers, in order to assess repro-
ducibility and to obtain reference values.
definition and assessment of study endpoints
The primary endpoint was defined prior to the collection of data 
as a composite of all adverse cardiovascular events: all-cause 
mortality, HF (requiring initiation or change in HF medication 
or requiring hospitalisation), hospitalisation for cardiac reasons, 
arrhythmia (symptomatic and recorded, or requiring treatment), 
thromboembolic events (ischaemic cerebrovascular accident, 
pulmonary embolism or myocardial infarction) or cardiac inter-
ventions (surgical or percutaneous). We defined the secondary 
endpoint as a composite of all-cause mortality or HF. All patients 
were annually evaluated at our outpatient clinic according to a 
standard protocol. Information was retrieved from electronic 
patient records. Survival status was checked in the Municipal 
Population Register. Ambiguous endpoint events were adjudi-
cated by two investigators (LWG and JWR-H) without knowl-
edge of any biomarker level. All patients who did not reach one 
of the endpoints were censored after 1 January 2018.
statistical analysis
Sample size calculation was performed and has been described 
previously.10 Continuous variables are represented as 
mean±SD or median (IQR). The X2 Mantel-Henszel test for 
trend or linear regression was performed to compare variables 
across the different quartiles of sST2. The correlation between 
sST2 and NT-proBNP was visualised with scatterplots, and the 
Spearman correlation coefficient was calculated.
Reproducibility of ST2 assay was assessed by Bland-Altman 
plots with corresponding limits of agreement. The coefficient 
of variation was determined by the following calculation; SD of 
the differences of two measurements divided by the mean of two 
measurements*100%.
The upper limit of normal was determined based on the 
97.5th percentile of sST2 levels in healthy volunteers. The 
97.5th percentile was estimated using 2log transformed sST2 
values and calculated with mean +1.96 SD.13 Sex specific refer-
ence values were calculated.
We used the Kaplan-Meier method to derive the cumula-
tive endpoint-free survival estimates. Survival curves stratified 
according to the quartile distribution of sST2 were compared 
with the log-rank test for trend. Cox proportional hazard 
regression was performed to assess the association between sST2 
and the endpoints. Multivariable analyses were performed to 
adjust for clinical characteristics, creatinine and NT-proBNP. 
Additivity of sST2 and sex was performed using an interaction 
term and tested with the log-likelihood ratio test. Likewise, 
linearity of sST2 was checked by adding a natural cubic spline 
with 3 df. Data on NT-proBNP were missing in <1% and were 
completed by imputation of the mean.
As post hoc analysis, patients were stratified according to 
moderate and complex congenital heart disease, and the associ-
ation between sST2 and both endpoints was assessed with Cox 
regression. Analyses were performed using IBM SPSS Statistics 
(V.24) and R (V.3.5.1, packages survival). A two-sided p value 
below 0.05 was considered statistically significant.
resulTs
baseline characteristics
In 590 of the 602 patients with a moderate to complex 
ACHD who were originally included in this cohort, sST2 was 
measured (online supplementary file 1). The median age of the 
patients was 33 (IQR 25–41) years, 248 (42%) were women 
and 90% was in New York Heart Association (NYHA) class I 
(table 1).
Median sST2 levels in women and men were 19.5 (IQR 
14.5–25.2) ng/mL and 28.5 (IQR 21.9–36.7) ng/mL, respec-
tively. sST2 was elevated in seven women (2.8%) and 15 
men (4.4%). Higher levels of sST2 were associated with oxygen 
saturation <90%, higher NYHA class, longer QRS duration, 
higher left ventricular end-diastolic volume and a larger right 
ventricular end diastolic annulus diameter (table 1). Highest 
sST2 levels were found in patients with Fontan, pulmonary 
arterial hypertension, Rastelli/reparation à l’etage ventriculaire 
and univentricular heart (figure 1). No significant correlation 
was found between levels of sST2 and NT-proBNP in men, and 
only a very weak correlation was found in women (r=−0.17, 
p=0.002). In moderate ACHD, a weak negative correlation was 
found (r=−0.19, p=0.001) (online supplementary file 2).
reference values and reproducibility
sST2 was measured in 142 healthy volunteers. One healthy 
volunteer was excluded from analysis because sST2 measure-
ment differed >20 SDs from the mean sST2 value of the healthy 
cohort and was seen as extreme outlier. sST2 was significantly 
higher in men than in women (p=0.002) but not associated with 
age (♂p=0.138, ♀p=0.334)(figure 2). Sex-specific upper limits 
of normal of sST2 were 44.50 ng/mL for women and 55.85 ng/
mL for men. Percentile levels of sST2 in healthy volunteers and 
patients with ACHD are summarised in online supplementary 
file 3. Reproducibility of the sST2 essay was good, with a coeffi-
cient of variation of 7.74% and limits of agreement of −5.59 ng/
mL to 7.61 ng/mL (online supplementary file 4).
Follow-up
Survival status was complete in 99.7%. Detailed follow-up 
data regarding the other endpoints were available in 585 
patients (99.2%). After a median of 5.8 (IQR 5.1–6.23) years 
of follow-up, the primary composite endpoint occurred in 
225 patients (38.5%). The secondary endpoint occurred in 
69 patients (11.8%). With regard to all separate components 
of the primary endpoint (ie, patients were not censored at 
the time of another endpoint than the endpoint of interest), 
the occurrence of events were: death (n=25), HF (n=59), 
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Age, years 33 (25-41) 34 (26-43) 33 (25-41) 33 (25-43) 31 (24-37) 0.039
Sex, women, n (%) 248 (42) 100 (68) 80 (54) 45 (30) 23 (16) <0.001
Surgical repair, n (%) 538 (91) 137 (93) 135 (91) 131 (88) 135 (93) 0.769
Age at surgical repair, years 3.8 (0.8–11.9) 4.4 (1.0–13.9) 3.3 (0.8–11.1) 3.6 (0.7–11.7) 3.3 (0.7–12.2) 0.324
Congenital diagnosis, complex, n (%)* 324 (55) 71 (48) 79 (53) 88 (59) 86 (59) 0.033
Cardiac medication use, n (%)† 211 (36) 55 (37) 48 (32) 56 (38) 52 (36) 0.956
Body mass index, kg/m2 24.8±4.4 25.3±4.6 24.6±3.9 24.9±4.7 24.1±4.2 0.040
Heart rate, beats/minute 74±13 74±13 72±14 74±13 75±13 0.332
Systolic blood pressure, mm Hg 126±16 126±19 126±16 126±14 127±16 0.682
O2saturation <90%, n (%) 17 (3) 0 (0) 2 (1) 5 (3) 10 (7) <0.001
NYHA class, II or III, n (%) 61 (10) 10 (7) 10 (7) 18 (12) 23 (16) 0.004
electrocardiography
Rhythm, n (%) 0.153
  Sinus rhythm 509 (86) 121 (82) 131 (88) 135 (91) 122 (84)
  Paced rhythm 44 (8) 13 (9) 10 (7) 6 (4) 15 (10)
  Other 37 (6) 13 (9) 8 (5) 8 (5) 8 (6)
QRS duration, ms 113 [100-137] 110 [95-128] 112 [99-136] 115 [101-148] 115 [104-138] 0.002
echocardiography
Left atrial volume, mL/m2 21 [16 -29] 20 [16-29] 21 [15-29].5 20 [15-29] 21 [15-30] 0.656
Left ventricular end-diastolic volume, mL/m2*‡ 63±19 60±20 63±18 64±17 66±20 0.019
Left ventricular ejection fraction, %‡ 56±8 57±8 56±9 56±7 56±7 0.218
Right ventricular end diastolic annulus, mm 42±8 41±8 41±8 43±8 44±8 0.002
Right ventricular fractional area change, % 38±11 40±12 38±10 37±12 38±11 0.200
Systemic ventricular function, n (%) 0.202
  Normal 296 (50) 81 (55) 79 (53) 67 (45) 69 (48)
  Mildly impaired 207 (35) 48 (33) 47 (32) 59 (40) 53 (37)
  Moderately impaired 69 (12) 13 (9) 17 (11) 20 (13) 19 (13)
  Severely impaired 18 (3) 5 (3) 6 (4) 3 (2) 4 (3)
E/A ratio 1.6±0.7 1.7±0.8 1.6±0.6 1.6±0.6 1.7±0.6 0.910
E′ wave, m/s 8.2±2.6 8.3±2.7 8.1±2.5 8.0±2.5 8.5±2.6 0.011
E/E′ ratio 11.6±5.1 12.1±5.7 11.7±4.1 11.4±5.0 11.2±5.3 0.220
Severe valvular dysfunction, n (%)§ 83(14) 16 (11) 21 (14) 21 (14) 25 (18) 0.136
laboratory results
Creatinine, μmol/L 77±18 74±15 73±13 79±17 82±24 <0.001
NT-proBNP, pmol/L¶ 15 [7-33] 18 [8-36] 13 [7-33] 15 [6-30] 15 [6-29] 0.481
sST2, ng/mL 24.3 (18.0–32.2) 14.0 (11.4–16.1) 21.0 (19.5–22.5) 28.1 (26.1–30.0) 39.9 (34.9–49.6) -
*Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or 
pulmonary arterial hypertension (1).
†Beta-blocker (=90, 15%), ACE inhibitor (n=88, 15%), diuretic (n=71,12%), antiarrhythmic (n=53, 9%) angiotensin receptor blocker (n=36, 6%).
‡Left-sided volumes were not measured in patients with a systemic right ventricle, univentricular heart, pulmonary hypertension or a poor acoustic window. 
§Defined as maximal aortic or pulmonary valve velocity >4.0 m/s; grade 3 or 4 out of 4 aortic, pulmonary or mitral valve regurgitation; or grade 4 out of 4 tricuspid valve 
regurgitation.
¶Analysis was performed based on 2log transformed values.
NT-proBNP, N terminal pro-B type brain natriuretic peptide; NYHA,New York Heart Association; sST2,soluble suppression of tumourigenicity-2.
hospitalisation (n=177), arrhythmia (n=127), thromboembolic 
event (n=29) and cardiac intervention (n=135).
ssT2 and associations with study endpoints
Endpoint-free survival stratified according to the quartile distri-
bution of sST2 showed that patients in the lowest sST2 quar-
tile (Q1; sST2 18.0<ng/mL) had a significant better primary 
and secondary endpoint-free survival than patients in higher 
quartiles (figure 3).
Multivariable analysis with continuous sST2 levels and adjust-
ment for age, sex and creatinine showed a significant association 
between sST2 and both the primary and secondary endpoints 
(table 2). Additional adjustment for NT-proBNP showed that a 
twofold increase in sST2 level was significantly associated with 
an increased risk of both endpoints. sST2 was also independently 
associated with the endpoints after full adjustment for age, sex 
and other clinical characteristics (table 2). Nevertheless, adjust-
ment for NT-proBNP additional to clinical characteristics leads 
to non-significant results.
Stratified analysis according to moderate and complex ACHD 
showed that sST2 was significantly associated with both the 
primary and secondary endpoint in complex ACHD. Moreover, 
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Figure 1 sST2 levels according to the different congenital diagnosis 
groups. The median sST2 level in each group is indicated by the 
horizontal line. ccTGA, congenital corrected transposition of the great 
arteries; PAH, pulmonary arterial hypertension; sST2, soluble suppression 
of tumourigenicity-2.
Figure 2 sST2 levels according to age decades and sex in 
healthy volunteers shown by boxplots. sST2, soluble suppression of 
tumourigenicity-2.
sST2 remained significantly associated with the primary endpoint 
after full adjustment for clinical characteristics and NT-proBNP 
in complex ACHD. In moderate ACHD, sST2 yielded no prog-
nostic value (table 3).
sex-specific differences of ssT2
Sex and sST2 showed a significant interaction; therefore, we 
performed a stratified post hoc analysis by sex. Women were 
older, had a higher heart rate, lower systolic blood pressure and 
higher NT-proBNP levels than men (online supplementary file 
5). Survival analysis showed that women in the fourth quartile 
of sST2 (sST2 >25.2 ng/mL) were at higher risk of endpoints. In 
men, there was no significant difference in endpoint-free survival 
among sST2 quartiles (online supplementary file 6). Analysis of 
continuous levels showed that in women sST2 was strongly asso-
ciated with the endpoints, independent of age, creatinine and 
NT-proBNP. In men, these associations were absent (table 4).
dIsCussIOn
This study investigated the prognostic value of sST2 in a large 
prospective cohort of adults with congenital heart disease. 
Higher levels of sST2 were found in patients with more complex 
congenital heart disease. Moreover, levels of sST2 were signifi-
cantly associated with cardiovascular events, even independent of 
the established biomarker NT-proBNP. Diagnosis-specific anal-
ysis showed a significant prognostic value for sST2 in complex 
ACHD independent of clinical characteristics and NT-proBNP, 
while in moderate ACHD, sST2 yielded no prognostic value. We 
also revealed important sex-specific differences of sST2; both 
in healthy controls and patients with ACHD, sST2 was lower 
in woman throughout all age categories. In addition, whereas 
sST2 was significantly associated with cardiovascular events in 
woman, this association was absent in men.
Previous reports
As sST2 has been investigated extensively in HF, it has only been 
described once in ACHD. Laqqan et al7 investigated sST2 in 
complex ACHD patients with a wide age range (12–70 years) 
and identified sST2 as strong prognostic biomarker. The prog-
nostic value of sST2 in patients with chronic and acute HF has 
been established firmly and is described by Aimo et al in two 
meta-analysis. In both populations, sST2 aids the risk strati-
fication.5 6 In patients with acute HF, sST2 levels rose in the 
period prior to readmission for HF or death and serial sST2 
measurements better predicted adverse outcomes compared 
with a single measurement, independent of serial NT-proBNP 
measurements.14 Finally, another study showed that higher levels 
of sST2 were predictive of survival after transcathether aortic 
valve implantation in patients with aortic stenosis.15
Pathophysiology of ssT2
Soluble ST2 is the circulating form of the transmembrane ST2 
ligand, which is the receptor for interleukin-33. sST2 acts as a 
decoy receptor for interleukin-33 and therefore increased sST2 
levels undermine the effects of the interleukin-33/ST2 ligand 
interaction.16 17 The interleukin-33/ST2 ligand signalling plays an 
important role in protecting the myocardium against maladap-
tive hypertrophy and fibrosis. As sST2 blocks this IL-33/ST2 
ligand complex, these cardiac protective effects will be abolished 
and ventricular failure may develop.18 In our study, sST2 and 
NT-proBNP levels were not correlated in complex ACHD. In the 
first and only study previously investigating sST2 in patients with 
complex ACHD, only a very weak correlation was found between 
sST2 and NT-proBNP (r=0.29, p<0.001).7 This may suggest 
that sST2 is involved in another pathophysiological pathway than 
NT-proBNP regarding myocardial adaptation and dysfunction.
Besides the association with myocardial stress, sST2 is also 
known for its relation with inflammatory and immune processes.17 
sST2 has been investigated as inflammatory marker in numerous 
diseases such as asthma, chronic obstructive pulmonary disease, 
collagen vascular diseases, trauma and sepsis.19 Although it 
is unlikely that sST2 levels were influenced by inflammatory 
processes in our patients, we cannot preclude that sST2 levels may 
have been influenced by other unknown processes.
ssT2 in healthy individuals
Reference values established in this study were higher for both 
sexes than reference values described in previous studies using 
the same ST2 assay.20–22 However, median/mean sST2 levels 
were comparable with most values reported in literature.21 22 A 
reason for the high reference values may be the relatively limited 
number of healthy volunteers and therefore the stronger influ-
ence of outliers. These high reference values could explain the 
relatively low number of ACHD patients with an elevated level of 
sST2 in our study. Identifying patients in our study with elevated 
sST2 levels based on reference values from the Framingham 
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Figure 3 Survival regarding the primary endpoint (any cardiovascular event) and the secondary endpoint (death or heart failure) stratified according 
to the quartile distribution of sST2. Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile; sST2, soluble suppression of tumourigenicity-2.
Table 2 Associations between sST2 and the primary (any cardiovascular event) and secondary endpoints (death or heart failure), with adjustment 
for clinical characteristics
hr per twofold higher 
value 95% CI P value
Any cardiovascular event (n=225)
sST2 (univariable) 1.30 1.07 to 1.57 0.007
Adjusted for age and sex 1.47 1.19 to 1.81 <0.001
Adjusted for age, sex and creatinine 1.44 1.17 to 1.78 <0.001
Adjusted for age, sex and NT-proBNP 1.28 1.04 to 1.57 0.022
Adjusted for age, sex, NT-proBNP and creatinine 1.28 1.03 to 1.58 0.025
Adjusted for age, sex, rhythm and systemic ventricular function 1.46 1.19 to 1.79 <0.001
Adjusted for age, sex, congenital diagnosis*, NYHA class and cardiac medication 1.29 1.05 to 1.58 0.016
Full model† 1.28 1.05 to 1.59 0.017
Full model† and NT-proBNP 1.19 0.96 to 1.48 0.106
death or heart failure (n=69)
sST2 (univariable) 1.48 1.04 to 2.10 0.029
Adjusted for age and sex 2.23 1.50 to 3.30 <0.001
Adjusted for age, sex and creatinine 2.16 1.45 to 3.22 <0.001
Adjusted for sex, age and NT-proBNP 1.48 0.99 to 2.22 0.059
Adjusted for sex, age, NT-proBNP and creatinine 1.57 1.03 to 2.39 0.036
Adjusted for age, sex, rhythm and systemic ventricular function 2.13 1.46 to 3.12 <0.001
Adjusted for age, sex, congenital diagnosis*, NYHA class and cardiac medication 1.60 1.10 to 2.34 0.015
*Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or 
pulmonary arterial hypertension (1). 
†Adjusted for age, sex, creatinine, sinus rhythm, systemic ventricular function, congenital diagnosis, NYHA class 2–3 and cardiac medication. Analysis including all covariates (full 
model) was not performed for the secondary endpoint due to insufficient statistical power.
NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.
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Table 3 Stratified analysis for the association between sST2 and the primary endpoint (any cardiovascular event) and secondary endpoints (death 
or heart failure) according moderate and complex adult congenital heart disease (ACHD)
Moderate (n=266) Complex (n=324)
hr* 95% CI P value hr* 95%  CI P value
Any cardiovascular event n=73 n=152
sST2 (univariable) 0.81 0.57 to 1.15 0.234 1.61 1.27 to 2.03 <0.001
Adjusted for age and sex 0.88 0.58 to 1.34 0.561 1.77 1.37 to 2.28 <0.001
Adjusted for age, sex and creatinine 0.89 0.59 to 1.35 0.591 1.73 1.34 to 2.23 <0.001
Adjusted for age, sex and NT-proBNP 0.83 0.56 to 1.24 0.368 1.53 1.19 to 1.97 <0.001
Adjusted for age, sex, NT-proBNP and creatinine 0.83 0.56 to 1.24 0.363 1.53 1.18 to 1.99 0.001
Adjusted for age, sex, rhythm and systemic ventricular function 0.86 0.56 to 1.31 0.478 1.76 1.37 to 2.25 <0.001
Adjusted for age, sex, NYHA class and cardiac medication 0.90 0.59 to 1.37 0.620 1.40 1.10 to 1.78 0.007
Adjusted for full model† 0.86 0.56 to 1.30 0.470 1.37 1.07–1.76 0.013
Adjusted for full model† and NT-proBNP 0.80 0.54 to 1.21 0.294 1.31 1.01 to 1.69 0.043
death or heart failure n=15 n=54
sST2 (univariable) 0.52 0.24 to 1.14 0.100 1.87 1.25 to 2.80 0.002
Adjusted for age and sex – – – 2.68 1.75 to 4.11 <0.001
Adjusted for age, sex and creatinine – – – 2.53 1.62 to 3.95 <0.001
Adjusted for age, sex and NT-proBNP – – – 1.88 1.20 to 2.95 0.006
Adjusted for age, sex, NT-proBNP and creatinine – – – 1.93 1.20 to 3.12 0.007
Moderate ACHD: arterial switch operation, aortic stenosis or aortic coarctation.
Complex ACHD: tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or pulmonary arterial hypertension. Due to only a limited number of events, no further 
adjustment for clinical characteristics was performed regarding the secondary endpoint.
*HRs are expressed per twofold higher sST2 level. 
†Adjusted for age, sex, creatinine, sinus rhythm, systemic ventricular function, NYHA class 2–3 and cardiac medication.
NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.
Table 4 Stratified analysis for the association between sST2 and the primary endpoint (any cardiovascular event) and secondary endpoint (death 
or heart failure) according to women and men
Women Men
hr* 95%  CI P value hr* 95%  CI P value
Any cardiovascular event n=96 n=129
sST2 (univariable) 1.80 1.30 to 2.49 <0.001 1.19 0.90 to 1.56 0.223
Adjusted for age 1.72 1.22 to 2.44 0.002 1.30 0.99 to 1.71 0.063
Adjusted for age and creatinine 1.71 1.22 to 2.41 0.002 1.28 0.97 to 1.69 0.080
Adjusted for age and NT-proBNP 1.49 1.04 to 2.12 0.029 1.16 0.89 to 1.51 0.274
Adjusted for age, NT-proBNP and creatinine 1.48 1.04 to 2.11 0.029 1.18 0.89 to 1.55 0.248
Adjusted for age, rhythm and systemic ventricular function 1.67 1.20 to 2.33 0.002 1.28 0.98 to 1.68 0.071
Adjusted for age, congenital diagnosis†, NYHA class and cardiac 
medication
1.23 0.87 to 1.75 0.240 1.30 0.99 to 1.70 0.056
Adjusted for full model‡ 1.26 0.89 to 1.79 0.190 1.28 0.97 to 1.69 0.076
Adjusted for full model‡ and NT-proBNP 1.17 0.81 to 1.69 0.407 1.18 0.89 to 1.56 0.250
death or heart failure n=40 n=29
sST2 (univariable) 2.72 1.67 to 4.44 <0.001 1.47 0.81 to 2.65 0.201
Adjusted for age 2.68 1.55 to 4.63 <0.001 1.83 1.03 to 3.23 0.039
Adjusted for age and creatinine 2.68 1.55 to 4.62 <0.001 1.61 0.88 to 2.94 0.125
Adjusted for age and NT-proBNP 2.03 1.12 to 3.69 0.020 1.18 0.69 to 2.00 0.547
Adjusted for age, NT-proBNP and creatinine 2.04 1.12 to 3.71 0.020 – § – – 
Analysis including all covariates (full model) was not performed for the secondary endpoint due to insufficient statistical power.
*HRs are expressed per twofold increase in sST2 level. P value of interaction between sex and sST2=0.047 (primary endpoint) and p=0.104 for secondary endpoint.
†Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or 
pulmonary arterial hypertension (1).
‡Adjusted for age, creatinine, sinus rhythm, systemic ventricular function, congenital diagnosis, NYHA class 2–3 and cardiac medication.
§Insufficient statistical power to perform analysis.
NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.
Heart Study resulted in 19 women (7.7%) (>33.2 ng/mL) and 38 
men (11.1%) (>47.6 ng/mL) with an elevated sST2. This would 
mean that in 9.7% of the patients sST2 was elevated in contrast 
to the 3.7% we identified.
Although sST2 levels measured in patients with ACHD seemed 
comparable with the ones found in the healthy volunteers, it is 
unclear whether sST2 has the same prognostic value in healthy 
volunteers as in patients with ACHD. A study investigating sST2 
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Key messages
What is already known on this subject?
 ► Soluble suppression of tumourigenicity-2 (sST2) is emerging 
as new prognostic biomarker in patients with heart failure. 
Only very limited data are available on sST2 in adults with 
congenital heart disease (ACHD), while this population is 
characterised by a high incidence of heart failure.
What might this study add?
 ► In patients with ACHD who are seen at the outpatient clinic, 
higher sST2 levels are associated with an increased risk of 
cardiovascular events, independent of N terminal pro-B type 
brain natriuretic peptide (NT-proBNP) levels. This association 
was specifically present in women and adults with complex 
congenital heart disease.
how might this impact on clinical practice?
 ► sST2 can be a potential new prognostic biomarker for 
risk stratification in ACHD. Besides NT-proBNP, an sST2 
measurement should be considered mainly in patients with 
complex ACHD. Sex-specific cut-off levels should be applied.
in a Finnish healthy cohort showed that sST2 did not improve 
long-term prediction of cardiovascular events.23 In contrast, the 
Framingham Heart Study found that higher sST2 preceded cardiac 
adverse events during a mean follow-up of 11.3 years in the general 
population.24
sex-specific differences of ssT2
Our study in healthy volunteers found that sST2 levels were 
significantly lower among women than men; this finding is 
consistent with previous studies.21 22 Normal ranges studied in 
the Framingham Heart Study found that both sex and age are 
important determinants of sST2 levels. They described that 
women taking oestrogen replacement therapy had lower levels of 
sST2,13 suggesting that hormone release may explain the sex-dif-
ference in sST2 levels. However, another study investigating the 
association between ssST2 and hormones in healthy men and 
women did not find an independent association.25 Currently, 
there has been no clear explanation for these sex-differences and 
whether sST2 synthesis or secretion is under hormonal control 
or not.
The patients in our study were much younger compared 
with the general HF population. Most women presumably are 
premenopausal and may use hormone replacement as anticon-
ception. This could be an explanation for the interaction between 
sST2 and sex that we found. Unfortunately, we had no data on 
hormone levels. Further research is warranted to elucidate the 
conflicting results on hormonal influences and sST2 in premeno-
pausal women. This is of particular interest in the ACHD popu-
lation, which is characterised by a relatively young age.
There was no significant association between sST2 and the 
primary endpoint in men, and it seemed that the height of sST2 
and the associated risk reached a ceiling, creating a situation in 
which higher sST2 levels do not reflect higher risks. Although 
there are no data to support this, a possible explanation might 
be that men have more fluctuating and extreme levels of sST2. 
Hormonal influences in women might cause more stable and less 
extreme sST2 levels leading to a more stable prognostic effect of 
sST2 over time in women.
Clinical perspectives
sST2 may specifically be useful as prognostic biomarker in 
stable adults with complex congenital heart disease. Therefore, 
an sST2 measurement could be considered in these patients, 
besides an NT-proBNP measurement. Our study was conducted 
in clinically stable adult patients, and it would be interesting 
to know whether an increase in sST2 over time reflects clin-
ical worsening. Serial measurements of NT-proBNP have been 
investigated in ACHD, and increased NT-proBNP levels were 
found before the occurrence of cardiovascular events.26 sST2 has 
a narrower biological variation in comparison to NT-proBNP,27 
which is an advantage when measuring a biomarker repeatedly. 
For this reason, sST2 may be a very suitable biomarker in clin-
ical practice to monitor patients over time. Patients with ACHD 
are characterised by a high need for reinterventions; 23% of the 
patients in our cohort needed a reintervention during follow-up. 
A biomarker that could aid with the right timing of reinterven-
tions is therefore highly desirable in this population.
limitations
Serum samples were stored for a duration by −80°C before sST2 
was measured. It is unknown whether sST2 levels are affected by 
this long storage period; however, one study showed that sST2 
is stable in plasma samples for a maximum storage period of 1.5 
years at −80°C.28 In our study, there was no correlation found 
between storage time and sST2 levels.
A heterogeneous group of diagnoses are included in this ACHD 
cohort. sST2 levels were higher in the patients with complex 
ACHD, in which sST2 yielded a strong prognostic value. In 
contrast, no prognostic value of sST2 was found in moderate 
ACHD. Unfortunately, diagnoses-specific subgroup analysis were 
restricted by the limited sample size within each diagnosis group. 
Patients with isolated repaired atrial or ventricular septal defect 
were not included in this study due to the expected low number 
of events. This should be kept in mind when extrapolating the 
results to other ACHD cohorts. sST2 is a relatively expensive 
biomarker and currently not available in standard laboratories. 
Implementing sST2 in the current risk stratification is therefore 
challenging. However, over the past years, sST2 has increasingly 
been used in patients with HF, potentially expanding the avail-
ability of the ST2 assay in the future.
COnClusIOn
sST2 is significantly associated with adverse cardiovascular 
events in patients with complex ACHD, independent of the 
conventional biomarker NT-proBNP. Sex-specific analyses 
revealed a strong association between sST2 and cardiovascular 
events in women; however, this association was absent in men. 
These sex differences of sST2 need further clarification. None-
theless, sST2 seems to be a potential new prognostic biomarker 
in patients with ACHD.
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